Expression of concern--effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial. — VialBase Research

Summary

This record is not a study. It is a formal Expression of Concern published by The Lancet in 2013 concerning the randomised, double-blind, placebo-controlled trial of the effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients — the pivotal obesity trial from which tesofensine’s headline efficacy claim derives. PubMed indexes the item with the publication types Editorial, Comment, and Expression of Concern, and lists no authors, which is the normal pattern for an integrity notice issued by a journal’s editors rather than by named investigators. The PubMed record contains no abstract, so the substance of the editors’ concerns is not recoverable from the indexed metadata and must be read in the notice as published in the journal. What can be stated from the record with certainty, and what matters for anyone assessing tesofensine, is the bare fact itself: the journal that published the pivotal tesofensine obesity trial subsequently found cause to attach a public Expression of Concern to it. An Expression of Concern is the mechanism a journal uses when it has reason to question a paper’s reliability but has not concluded a retraction; the paper remains in the literature with a flag attached to it. That flag is a permanent part of tesofensine’s evidence base.

Key Findings

• The Lancet published a formal Expression of Concern regarding the randomised, double-blind, placebo-controlled trial of tesofensine on bodyweight loss, body composition, and quality of life in obese patients (Lancet 2013;381(9873):1167)
• PubMed publication types are Editorial, Comment, and Expression of Concern — this is a journal integrity notice, not new research data
• The notice is unsigned; no authors are listed in the PubMed record, consistent with an editorial issued by the journal
• The flagged trial is the pivotal obesity study behind tesofensine’s marketed weight-loss claim, not a peripheral publication
• No abstract is indexed, so the specific grounds for the editors’ concern must be read in the published notice rather than inferred from metadata

Relevance to Tesofensine

Every consumer-facing claim about Tesofensine as a weight-loss compound traces back to the pivotal randomised, double-blind, placebo-controlled obesity trial published in The Lancet — and that trial carries a published Expression of Concern from the journal that printed it. This is the single most important honest signal on the compound and it cannot be treated as a footnote. It does not mean the trial’s results are false; an Expression of Concern is a flag, not a retraction. It does mean that the headline efficacy figure most often quoted for tesofensine rests on a paper whose own journal has publicly questioned its reliability, and that anyone repeating that figure without disclosing the flag is presenting the evidence base as cleaner than it is. Read this note together with the Lancet letter on under-reporting of adverse effects of tesofensine (PMID 23849924): efficacy under an Expression of Concern and contested adverse-event reporting are the two halves of the same integrity problem.

Citation

Expression of concern—effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial. Lancet (London, England). 2013;381(9873):1167. doi:10.1016/S0140-6736(13)60778-3.

See Also

• Parent compound: Tesofensine